Innoviva Specialty Therapeutics develops therapies targeting critical care and infectious diseases, focusing on conditions caused by drug-resistant microorganisms. Their products, including GIAPREZA and XERAVA, provide effective treatment options for life-threatening infections identified by global health organizations.
Funding
Funding not disclosed
Founders
Product
Problem
Patients in critical care and those with serious infections, especially those caused by drug-resistant microorganisms, face life-threatening situations with limited effective treatment options. The increasing prevalence of these infections poses a significant challenge to global health organizations.
Solution
Innoviva Specialty Therapeutics develops and delivers innovative therapies focused on addressing critical care needs and combating infectious diseases. The company's marketed products provide both new and established standards of care for treating serious, life-threatening conditions. By focusing on areas of high unmet need, Innoviva Specialty Therapeutics aims to advance treatment options for patients facing emerging illnesses and drug-resistant microorganisms. Their therapies are grounded in thorough research and a commitment to quality, providing solutions for urgent infections identified by leading public health organizations.
Target Audience
The primary target audience includes patients in critical care, individuals suffering from serious infections, and healthcare providers seeking effective treatment options for drug-resistant microorganisms.
Features
- GIAPREZA® (angiotensin II) for critical care.
- XERAVA® (eravacycline) for infectious diseases.
- XACDURO® (sulbactam for injection; durlobactam for injection) for infectious diseases.
- Focus on therapies targeting drug-resistant microorganisms.
- Development pipeline for future therapies.